原发性甲状腺淋巴瘤生存趋势与相关因素:基于SEER数据库1975-2021年分析
该回顾性队列研究利用SEER数据库纳入1975-2021年确诊的2465例≥20岁原发性甲状腺淋巴瘤患者,评估生存趋势及预后因素。结果显示2000年后确诊者生存显著改善,年龄≥70岁及区域/远处转移与较差疾病特异性生存相关,化疗联合放疗者10年DSS最高(86.6%)。
要点
- 2000年后确诊的PTL患者生存显著改善(p<0.001)。
- 年龄≥70岁、区域及远处转移与较差DSS独立相关。
- 化疗联合放疗者10年DSS达86.6%,优于其他治疗模式。
核心结论
- 近几十年来原发性甲状腺淋巴瘤生存显著改善,可能反映治疗进步(尤其化疗联合放疗)及诊断提前和分期分布变化。
研究设计与样本
- 回顾性队列研究,使用SEER数据库纳入1975-2021年确诊、年龄≥20岁的原发性甲状腺淋巴瘤患者2465例。
主要发现
- 中位随访83个月(IQR 24-156),中位总生存150个月,1年、5年、10年OS率分别为84.9%、72.9%、57.7%。
- 1年、5年、10年疾病特异性生存率分别为89.1%、83.7%、80.5%。
- 年龄≥70岁与较差DSS相关(HR=5.77;CI 2.71-12.32,p<0.001)。
- 区域转移(HR=1.45;CI 1.04-2.02;p=0.03)和远处转移(HR=1.53;CI 1.17-1.99;p=0.002)与较差DSS相关。
- 化疗联合放疗者10年DSS最高(86.6%),优于化疗 alone(77.2%)、放疗 alone(77.0%)和无治疗(68.2%)。
关键数值与推荐
- 治疗分类为化疗联合放疗(可含手术)、单纯化疗、单纯放疗或无治疗。
- 生存分析采用Kaplan-Meier曲线和Cox比例风险模型。
临床怎么用
- 对PTL患者应关注年龄及分期,高龄或转移性患者预后较差。
- 化疗联合放疗与最高10年DSS相关,支持其作为PTL治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Primary thyroid lymphoma (PTL) is a rare malignancy, comprising less than 5% of all thyroid cancers and about 2.5% of lymphomas. Historically, treatment with surgery and radiation yielded poor outcomes. The advent of combined chemotherapy and radiation has improved survival, but long-term trends and prognostic factors remain underexplored. This study aimed to characterize the clinical and demographic features of PTL, evaluate changes in survival over time, and identify factors independently associated with survival. Methods: A retrospective cohort study was conducted using Surveillance, Epidemiology, and End Results data from PTL patients aged ≥20 years, diagnosed between 1975 and 2021. Variables analyzed included age, sex, race/ethnicity, lymphoma subtype, stage, and treatment modality. Survival outcomes were estimated using Kaplan-Meier curves, and Cox proportional hazards models were used to identify factors associated with survival. Treatment was categorized as chemotherapy plus radiation (with or without surgery), chemotherapy alone, radiation alone, or no treatment. Results: A total of 2465 patients were included; 76% (n = 1,874) were diagnosed from 2001 to 2021. Median age at diagnosis was 67 years (interquartile range [IQR]: 56-77); 69.9% (n = 1723) were female, and 88.8% (n = 2189) were White. The most common subtype was diffuse large B-cell lymphoma (62.5%, n = 1540). Median follow-up was 83 months (IQR: 24-156). Median overall survival (OS) was 150 months, with 1-, 5-, and 10-year OS rates of 84.9%, 72.9%, and 57.7%, respectively. Disease-specific survival (DSS) rates at the same time points were 89.1%, 83.7%, and 80.5%. Survival significantly improved for patients diagnosed after 2000 (p < 0.001). Variables associated with poorer DSS survival included age ≥70 years (hazard ratio [HR] = 5.77; confidence interval [CI] 2.71-12.32, p < 0.001), regional metastatic disease (HR = 1.45; CI 1.04-2.02; p = 0.03) and distant metastatic disease (HR = 1.53; CI 1.17-1.99; p = 0.002). The highest 10-year DSS (86.6%) was seen in those receiving combined chemotherapy and radiation, outperforming chemotherapy alone (77.2%), radiation alone (77.0%), and no treatment (68.2%). Conclusion: PTL survival has significantly improved in recent decades, which may reflect both advances in treatment, particularly the combined use of chemotherapy and radiation, and shifts in disease presentation, including earlier diagnosis and changes in stage distribution.
引用
- Toloza FJK, Gubbi S, Klubo-Gwiezdzinska J, et al. Trends in Survival and Factors Associated with Survival in Primary Thyroid Lymphoma: A SEER-Based Analysis (1975-2021). Thyroid. 2025. PMID: 40737210. doi:10.1177/10507256251363141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。